Does PSA screening actually reduce deaths from prostate cancer?
Yes, the best evidence shows it does, but the effect is smaller than many people think. The most definitive recent data comes from the CAP trial, a massive randomized controlled trial in the UK that followed over 400,000 men for a median of 15 years. It found that a single invitation for a PSA test reduced the risk of dying from prostate cancer by about 8% (rate ratio 0.92) [1]. In absolute terms, this means that among 1,000 men invited for screening, about 7 would die of prostate cancer, compared to about 8 among 1,000 men not invited — a difference of roughly 1 death prevented per 1,000 men screened over 15 years [1]. This is a statistically significant but modest benefit.
Other large studies support this finding from different angles. An ecological study of all 3,143 US counties found that counties with higher PSA screening rates had a 10% lower prostate cancer mortality rate in subsequent years [4]. A large study of US veterans (over 45,000 men) found that any prior PSA screening was associated with a roughly 40% lower risk of dying from prostate cancer for both Black and White men [3]. While these observational studies can't prove cause and effect as strongly as a randomized trial, their consistent message — that screening is linked to fewer deaths — adds weight to the conclusion.
What's the catch? The problem of overdiagnosis.
The main downside of PSA screening is that it frequently detects prostate cancers that are slow-growing and would never have caused symptoms or death — a problem called overdiagnosis. This leads to unnecessary biopsies, anxiety, and treatments like surgery or radiation that can cause impotence and incontinence. The CAP trial showed that screening increased the detection of low-grade (Gleason score ≤6) and localized cancers, but did not reduce the detection of more aggressive, high-grade tumors [1]. This means many men were diagnosed and potentially treated for cancers that posed little threat.
Newer screening protocols are being tested to reduce this harm. Several trials have shown that using an MRI scan after an elevated PSA, and only doing a biopsy if the MRI is suspicious, can dramatically cut down on overdiagnosis. For example, the GÖTEBORG-2 trial found that using MRI and targeted biopsy (instead of standard systematic biopsy) reduced the detection of clinically insignificant (low-risk) prostate cancer by more than half (relative risk 0.43) [5]. The STHLM3-MRI trial showed a similar reduction in overdiagnosis (from 12% to 4% of men diagnosed with insignificant cancer) while still catching the same number of clinically significant cancers [8]. These approaches aim to keep the mortality benefit of screening while minimizing the harms.
Who benefits most from screening, and when should it stop?
The benefit of screening is not equal for everyone. Black men are at higher risk of both getting and dying from prostate cancer, and the evidence suggests they may benefit more from regular screening. A large VA study found that annual PSA screening was associated with a significant reduction in prostate cancer death for Black men (subdistribution hazard ratio 0.65), but not for White men [3][6]. This suggests that more intensive screening protocols may be particularly important for Black men.
For men over 70, the decision to continue screening should be more cautious. A recent cohort study of over 900,000 veterans found that the 10-year risk of dying from prostate cancer after age 70 was very low overall (0.26%), and that a man's PSA level between ages 65-69 was highly informative [2]. Men with a very low PSA (below 1 ng/mL) at that age had an extremely low risk of future prostate cancer death (0.10%), even if they were Black [2]. This means that for many older men, especially those with low PSAs, the harms of continued screening likely outweigh the small potential benefit.
About These Sources
This answer is built on 8 peer-reviewed studies — published from 2021 to 2025, 3 from 2024 or later, 8 in Q1 journals, collectively cited 863 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 50 papers retrieved from a database of over 500 million.
Sources used in this answer
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality
In the largest randomized trial on this topic (CAP, over 400,000 men), a single invitation for PSA screening reduced prostate cancer deaths by 8% over 15 years, but the absolute reduction was very small (0.69% vs 0.78% dying of the disease) [1].
Prostate Cancer Mortality in Men Aged 70 Years Who Recently Underwent Prostate-Specific Antigen Screening
In a cohort of over 900,000 US veterans, the 10-year risk of prostate cancer death after age 70 was very low (0.26% overall), and a PSA level below 1 ng/mL between ages 65-69 predicted an extremely low risk, even for Black men [2].
Association Between Prostate-Specific Antigen Screening and Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White US Veterans
In a retrospective cohort of over 45,000 US veterans, any prior PSA screening was associated with a roughly 40% lower risk of prostate cancer death for both Black and White men; annual screening was especially beneficial for Black men [3].
The Association of County-level Prostate-specific Antigen Screening with Metastatic Prostate Cancer and Prostate Cancer Mortality
This population-based ecological study of all US counties confirmed that higher PSA screening rates were associated with a 14% lower incidence of regional/distant prostate cancer and a 10% lower prostate cancer mortality at extended follow-up [7].
Results after Four Years of Screening for Prostate Cancer with PSA and MRI
The GÖTEBORG-2 trial showed that using MRI and targeted biopsy (vs. systematic biopsy) in men with elevated PSA reduced the detection of clinically insignificant prostate cancer by more than half (relative risk 0.43) over 4 years of screening [8].
Association between prostate-specific antigen screening and prostate cancer mortality in a racially diverse cohort of United States veterans.
In a diverse VA cohort, any prior PSA screening was associated with improved prostate cancer survival for both Black and White men, but annual screening was only significantly beneficial for Black men (subdistribution hazard ratio 0.68) [10].
Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only
The GÖTEBORG-2 trial (initial report) found that using MRI-targeted biopsy only (vs. systematic biopsy) in men with elevated PSA reduced the diagnosis of clinically insignificant cancer by half (0.6% vs 1.2%) [11].
MRI-Targeted or Standard Biopsy in Prostate Cancer Screening
The STHLM3-MRI trial found that using MRI with targeted and standard biopsy (if MRI was suspicious) was noninferior to standard biopsy for detecting clinically significant cancer, while reducing the detection of insignificant cancer from 12% to 4% [15].